Outpatient weekly neoadjuvant chemotherapy followed by radiotherapy for advanced nasopharyngeal carcinoma: high complete response and low toxicity rates

J-C Lin, J-S Jan, C-Y Hsu, R-S Jiang, W-Y Wang, J-C Lin, J-S Jan, C-Y Hsu, R-S Jiang, W-Y Wang

Abstract

Nasopharyngeal carcinoma (NPC) is a radiosensitive and chemosensitive tumour. The aim of this prospective study is to evaluate the toxicity and efficacy of an outpatient weekly neoadjuvant chemotherapy (NeoCT) plus radiotherapy for advanced NPC. From November 1998 to August 2001, 90 NPC patients meeting the following criteria were treated: (1) neck node >6 cm; (2) supraclavicular node metastasis; (3) skull base destruction/intracranial invasion plus multiple nodes metastasis; (4) multiple neck nodes metastasis with one of nodal size >4 cm; or (5) elevated serum LDH level. The NeoCT consists of cisplatin 60 mg m(-2), alternating with 5-fluorouracil 2500 mg m(-2) plus leucovorin 250 mg m(-2) (P-FL) by an outpatient weekly schedule for a total of 10 weeks. Local radiotherapy > or =70 Gy by conventional fractionation was delivered within 1 week after NeoCT. Patient compliance was rather good. Grade 3-4 toxicity of NeoCT included leucopaenia (7.8%), anaemia (18.9%), thrombocytopaenia (3.3%), nausea/vomiting (4.4%), and weight loss (1.1%). Response evaluated after NeoCT showed 73.3% complete response (CR) rate of primary tumour, 71.1% CR rate of neck nodes, and an overall CR rate of 57.8%. In all, 88 out of 90 patients received rebiopsy of primary tumour and 55 patients (62.5%) revealed pathological CR. After a median follow-up time of 24 months, one persistent disease and 18 relapses were noted. The 2-year nasopharynx disease-free, neck disease-free, distant disease-free, overall, and progression-free survival rates are 98.9, 95.9, 80.0, 92.1, and 77.5%, respectively. Preliminary data of the current study show that P-FL NeoCT plus radiotherapy is a low-toxic regimen with promising results on very advanced NPC patients and merits to be investigated in phase III trials.

Figures

Figure 1
Figure 1
Pretreatment CT scan (A, B) showed a big nasopharyngeal tumour with intracranial invasion in a patient presenting as multiple cranial nerve palsy. The tumour regressed completely with bony regeneration of the destructed skull base after 10-week neoadjuvant chemotherapy (C, D).
Figure 2
Figure 2
Overall and progression-free survival curves for all 90 patients.
Figure 3
Figure 3
Comparison of overall survival (A) and progression-free survival (B) according to tumour response after neoadjuvant chemotherapy using the Kaplan–Meier estimate and the log-rank test. CR=complete response.

References

    1. Al-Sarraf M, LeBlanc M, Giri PGS, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup Study 0099. J Clin Oncol 16: 1310–1317
    1. Chan ATC, Teo PML, Leung TWT, Leung SF, Lee WY, Yeo W, Choi PHK, Johnson PJ (1995) A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 33: 569–577
    1. Chan ATC, Teo PML, Ngan RK, Leung TW, Lau WH, Zee B, Leung SF, Cheung FY, Yeo W, Yiu HH, Yu KH, Chiu KW, Chan DT, Mok T, Yuen KT, Mo F, Lai M, Kwan WH, Choi P, Johnson PJ (2002) Concurrent chemotherapy–radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 20: 2038–2044
    1. Cheng SH, Jian JJM, Tsai SYC, Yen KL, Chu NM, Chan KY, Tan TD, Cheng JC, Leu SY, Hsieh CY, Huang AT (2000) Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 48: 1323–1330
    1. Chi KH, Chang YC, Guo WY, Leung MJ, Shiau CY, Chen SY, Wang LW, Lai YL, Hsu MM, Lian SL, Chang CH, Liu TW, Chin TH, Yen SH, Perng CH, Chen KY (2002) A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 52: 1238–1244
    1. Chua DTT, Sham JST, Choy D, Lorvidhaya V, Sumitsawan Y, Thongprasert S, Vootiprux V, Cheirsilpa A, Azhar T, Reksodiputro AH and the Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group (1998) Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Cancer 83: 2270–2283
    1. Cooper JS (2000) Concurrent chemotherapy and radiation therapy for advanced stage carcinoma of the nasopharynx. Int J Radiat Oncol Biol Phys 48: 1277–1279
    1. Cvitkovic E and the International Nasopharynx Cancer Study Group (INCSG) (1996) Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs radiotherapy alone in stage IV (⩾N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int J Radiat Oncol Biol Phys 35: 463–469
    1. Geara FB, Glisson BS, Sanguineti G, Tucker SL, Garden AS, Ang KK, Lippman SM, Clayman GL, Goepfert H, Peters LJ, Hong WK (1997) Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Results of a matched cohort study. Cancer 79: 1279–1286
    1. Hareyama M, Sakata K, Shirato H, Nishioka T, Nishio M, Suzuki K, Saitoh A, Oouchi A, Fukuda S, Himi T (2002) A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer 94: 2217–2223
    1. Hong RL, Ting LL, Ko JY, Hsu MM, Sheen TS, Lou PJ, Wang CC, Chung NN, Lui LT (2001) Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 19: 4305–4313
    1. Hong S, Wu HG, Chie EK, Bang YJ, Heo DS, Kim KH, Sung MW, Park CI (1999) Neoadjuvant chemotherapy and radiation therapy compared with radiation therapy alone in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 45: 901–905
    1. Huang SC, Lui LT, Lynn TC (1985) Nasopharyngeal cancer: study III. A review of 1206 patients treated with combined modalities. Int J Radiat Oncol Biol Phys 11: 1789–1793
    1. Lee AWM, Poon YF, Foo W, Law SCK, Cheung FK, Chan DKK, Tung SY, Thaw M, Ho JHC (1992) Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 23: 261–270
    1. Lin JC, Chen KY, Jan JS, Hsu CY (1996). Partially hyperfractionated accelerated radiotherapy and concurrent chemotherapy for advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 36: 1127–1136
    1. Lin JC, Jan JS (1999) Locally advanced nasopharyngeal cancer: long-term outcomes of radiation therapy. Radiology 211: 513–518
    1. Ma J, Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, Lu TX, Mo HY (2001) Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 19: 1350–1357
    1. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214
    1. Rossi A, Molinari R, Boracchi P, Vecchio MD, Marubini E, Nava M, Morandi L, Zucali R, Pilotti S, Grandi C, Ambrosini G, Cellini N, Chiavacci A, Colombo A, Fior SD, Maria DD, Felci U, Gabriele P, Laddaga M, Magno L, Marziano C, Olmi P, Prino A, Roncoroni L, Torretta A, Zampi G, Zorat PL, Palo GD (1988) Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local–regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol 6: 1401–1410
    1. Sanguineti G, Geara FB, Garden AS, Tucker SL, Ang KK, Morrison WH, Peters LJ (1997) Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys 37: 985–996
    1. Teo PML, Chan ATC, Lee WY, Leung TWT, Johnson PJ (1999) Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by adjunctive chemotherapy. Int J Radiat Oncol Biol Phys 43: 261–271
    1. Wolden SL, Zelefsky MJ, Kraus DH, Rosenzweig KE, Chong LM, Shaha AR, Zhang H, Harrison LB, Shah JP, Pfister DG (2001) Accelerated concomitant boost radiotherapy and chemotherapy for advanced nasopharyngeal carcinoma. J Clin Oncol 19: 1105–1110

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir